Previously validated strategies have focused on reducing the duration of neutropenia through interventions such as prophylactic administration of granulocyte colony-stimulating factors, which is often associated with a decrease in the incidence of infections and shorter hospitalizations in neutropenic patients, without an impact on mortality [23]–[25]. The gene discussed is CSF3; the disease is neutropenia.